Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

PharmaEssentia Acquires Myeloid Immune Checkpoint Antibody from WuXi Biologics

publication date: Oct 3, 2023

Taiwan’s PharmaEssentia, a global biopharma that develops hematology and oncology candidates, acquired a myeloid immune checkpoint antibody for solid tumors from WuXi Biologics Ireland. Myeloid checkpoints are receptors on the myeloid cell surface that mediate inhibitory signals, inhibiting cellular phagocytosis or suppressing T cells. PharmaEssentia will have exclusive global rights to research, develop, manufacture and commercialize the checkpoint antibody candidate. It will assume responsibility for all preclinical and clinical development efforts. PharmaEssentia will make an upfront payment plus pay milestones and sales royalties to WuXi Biologics. More details....

Stock Symbol: (TPEx: 6446)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital